Ex vivo biomarkers: functional tools to guide targeted drug development and therapy

References

• Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol.25(1), 118–145 (2007).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344(11), 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol.20(3), 719–726 (2002).
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol.17(9), 2639–2648 (1999).
   PubMed Web of Science ®Google Scholar
• Rosell R, Perez-Roca L, Sanchez JJ et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1mRNA expression. PLoS ONE4(5), e5133 (2009).
   PubMed Web of Science ®Google Scholar
• Sequist LV, Martins RG, Spigel D et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J. Clin. Oncol.26(15), 2442–2449 (2008).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med.353(2), 123–132 (2005).
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol.27(12), 2091–2096 (2009).
   PubMed Web of Science ®Google Scholar
• Messersmith WA, Ahnen DJ. Targeting EGFR in colorectal cancer. N. Engl. J. Med.359(17), 1834–1836 (2008).
   PubMed Web of Science ®Google Scholar
• Jones RB, Gordus A, Krall JA, MacBeath G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature439(7073), 168–174 (2006).
   PubMed Web of Science ®Google Scholar
• Schulze WX, Deng L, Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol. Syst. Biol.1, 2005.0008 (2005).
   PubMed Web of Science ®Google Scholar
• Uetz P, Stagljar I. The interactome of human EGF/ErbB receptors. Mol. Syst. Biol.2, 2006 0006 (2006).
   PubMedGoogle Scholar
• Bild AH, Potti A, Nevins JR. Linking oncogenic pathways with therapeutic opportunities. Nat. Rev. Cancer6(9), 735–741 (2006).
   PubMed Web of Science ®Google Scholar
• Gulmann C, Sheehan KM, Kay EW, Liotta LA, Petricoin EF 3rd. Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer. J. Pathol.208(5), 595–606 (2006).
   PubMed Web of Science ®Google Scholar
• Kwak EL, Clark JW, Chabner B. Targeted agents: the rules of combination. Clin. Cancer Res.13(18), 5232–5237 (2007).
   PubMed Web of Science ®Google Scholar
• Gal AA. In search of the origins of modern surgical pathology. Adv. Anat. Pathol.8(1), 1–13 (2001).
   PubMed Web of Science ®Google Scholar
• Gephardt GN, Zarbo RJ. Extraneous tissue in surgical pathology: a College of American Pathologists Q-Probes study of 275 laboratories. Arch. Pathol. Lab. Med.120(11), 1009–1014 (1996).
   PubMed Web of Science ®Google Scholar
• Srinivasan M, Sedmak D, Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am. J. Pathol.161(6), 1961–1971 (2002).
   PubMed Web of Science ®Google Scholar
• Mazurek GH, LoBue PA, Daley CL et al. Comparison of a whole-blood interferon g assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA286(14), 1740–1747 (2001).
   PubMed Web of Science ®Google Scholar
• Blumenthal RD, Goldenberg DM. Methods and goals for the use of in vitro and in vivo chemosensitivity testing. Mol. Biotechnol.35(2), 185–197 (2007).
   PubMed Web of Science ®Google Scholar
• Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J. Clin. Oncol.22(17), 3631–3638 (2004).
   PubMed Web of Science ®Google Scholar
• Rubio-Viqueira B, Jimeno A, Cusatis G et al. An in vivo platform for translational drug development in pancreatic cancer. Clin. Cancer Res.12(15), 4652–4661 (2006).
   PubMed Web of Science ®Google Scholar
• Irish JM, Kotecha N, Nolan GP. Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Nat. Rev. Cancer6(2), 146–155 (2006).
   PubMed Web of Science ®Google Scholar
• Schulz KR, Danna EA, Krutzik PO, Nolan GP. Single-cell phospho-protein analysis by flow cytometry. Curr. Protoc. Immunol.8, 8.17 (2007).
   Google Scholar
• Irish JM, Hovland R, Krutzik PO et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell118(2), 217–228 (2004).
   PubMed Web of Science ®Google Scholar
• Irish JM, Anensen N, Hovland R et al. Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood109(6), 2589–2596 (2007).
   PubMed Web of Science ®Google Scholar
• Kotecha N, Flores NJ, Irish JM et al. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell14(4), 335–343 (2008).
   PubMed Web of Science ®Google Scholar
• Irish JM, Czerwinski DK, Nolan GP, Levy R. Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood108(9), 3135–3142 (2006).
   PubMed Web of Science ®Google Scholar
• Ricciardi MR, McQueen T, Chism D et al. Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia19(9), 1543–1549 (2005).
   PubMed Web of Science ®Google Scholar
• Tong FK, Chow S, Hedley D. Pharmacodynamic monitoring of BAY 43–9006 (Sorafenib) in Phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. Cytometry B Clin. Cytom.70(3), 107–114 (2006).
   PubMed Web of Science ®Google Scholar
• Centeno BA, Enkemann SA, Coppola D, Huntsman S, Bloom G, Yeatman TJ. Classification of human tumors using gene expression profiles obtained after microarray analysis of fine-needle aspiration biopsy samples. Cancer105(2), 101–109 (2005).
   PubMedGoogle Scholar
• Symmans WF, Ayers M, Clark EA et al. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer97(12), 2960–2971 (2003).
   PubMed Web of Science ®Google Scholar
• Jimeno A, Kulesza P, Kincaid E et al. C-fos assessment as a marker of anti-epidermal growth factor receptor effect. Cancer Res.66(4), 2385–2390 (2006).
   PubMedGoogle Scholar
• Rubio-Viqueira B, Mezzadra H, Nielsen ME et al. Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays. Mol. Cancer Ther.6(2), 515–523 (2007).
   PubMedGoogle Scholar
• Jimeno A, Chan A, Cusatis G et al. Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Oncogene28(4), 610–618 (2009).
   PubMed Web of Science ®Google Scholar
• Srivastava S, Gray JW, Reid BJ, Grad O, Greenwood A, Hawk ET. Translational Research Working Group developmental pathway for biospecimen-based assessment modalities. Clin. Cancer Res.14(18), 5672–5677 (2008).
   PubMedGoogle Scholar
• Chau CH, Rixe O, McLeod H, Figg WD. Validation of analytic methods for biomarkers used in drug development. Clin. Cancer Res.14(19), 5967–5976 (2008).
   PubMed Web of Science ®Google Scholar
• Glassman RH, Ratain MJ. Biomarkers in early cancer drug development: limited utility. Clin. Pharmacol. Ther.85(2), 134–135 (2009).
   PubMed Web of Science ®Google Scholar
• Allison M. Is personalized medicine finally arriving? Nat. Biotechnol.26(5), 509–517 (2008).
   PubMed Web of Science ®Google Scholar
• Carden CP, Banerji U, Kaye SB, Workman P, de Bono JS. From darkness to light with biomarkers in early clinical trials of cancer drugs. Clin. Pharmacol. Ther.85(2), 131–133 (2009).
   PubMed Web of Science ®Google Scholar
• Davis JC, Furstenthal L, Desai AA et al. The microeconomics of personalized medicine: today’s challenge and tomorrow’s promise. Nat. Rev. Drug Discov.8(4), 279–286 (2009).
   PubMed Web of Science ®Google Scholar
• Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther.69(3), 89–95 (2001).
   PubMed Web of Science ®Google Scholar